These results suggest potential new therapeutic strategies for LRRK2-associated PD, including enhancing UCP expression or targeting UCP activity with agonists, inhibiting MCU functions, mitigating oxidative stress and restore mitochondrial function, in addition to blocking L-type channels. Here, UCP1 is linked to Parkinson disease.